Scientists discovered that obese mice produce too much of a protein called TMPRSS2 in their intestines, which interferes with hormones that help control blood sugar and appetite. This protein blocks the action of beneficial gut hormones (GLP-1 and ghrelin) that normally help regulate weight and glucose levels. When researchers removed or blocked this problematic protein in mice, the helpful hormones worked better again, and the mice showed improved blood sugar control. This finding could eventually help explain why obesity makes it harder for the body to regulate blood sugar naturally, and might lead to new treatments beyond current weight-loss medications.
The Quick Take
- What they studied: Whether a gut protein called TMPRSS2 interferes with the body’s natural hormones that control hunger, weight, and blood sugar in obese mice
- Who participated: Laboratory mice, including normal mice and specially bred mice with changes to their gut proteins, fed either regular or high-fat diets to study obesity
- Key finding: Obese mice had too much TMPRSS2 protein, which blocked important appetite-control and blood-sugar hormones. When scientists removed this protein or blocked it with medication, the helpful hormones worked properly again and blood sugar control improved significantly.
- What it means for you: This research suggests a new target for treating obesity and diabetes by controlling this gut protein, though human studies are still needed. It may eventually lead to treatments that work differently than current weight-loss medications.
The Research Details
Researchers used laboratory mice to study how a gut protein called TMPRSS2 affects hormones that control weight and blood sugar. They compared normal mice to specially engineered mice that couldn’t respond to TMPRSS2 in the way obese mice normally do. Some mice were fed regular food while others ate high-fat diets to become obese, allowing researchers to see how TMPRSS2 behaves differently in obesity.
The team used multiple approaches: they measured hormone levels in the blood, tested how well the mice’s bodies controlled blood sugar, and examined what happened when they removed the TMPRSS2 gene or used drugs to block it. They also studied the specific molecular pathways—the chemical communication systems—that TMPRSS2 uses to interfere with appetite and blood sugar hormones.
This type of research is important because it uses controlled laboratory conditions to understand the basic mechanisms of how obesity develops, which can’t easily be studied in humans. The findings help identify new targets for potential treatments.
Understanding why obesity breaks the body’s natural weight-control system is crucial for developing better treatments. Current weight-loss medications work by mimicking natural hormones, but they don’t fix the underlying problem. By identifying TMPRSS2 as a key player in obesity, scientists can develop treatments that restore the body’s own hormone systems rather than just replacing them with medications.
This research was published in JCI Insight, a respected peer-reviewed journal. The study used multiple experimental approaches and specially engineered mice to test cause-and-effect relationships, which is stronger evidence than observation alone. However, these are mouse studies, so results may not directly apply to humans. The specific sample sizes weren’t detailed in the abstract, which is a limitation for assessing statistical power.
What the Results Show
The researchers found that TMPRSS2 protein is present in high amounts in the intestines of obese mice. This protein interferes with two important hormones: GLP-1 (which helps control blood sugar and reduces appetite) and ghrelin (which signals hunger). In obese mice, TMPRSS2 was overactive and blocked these hormones from working properly.
When scientists created mice that couldn’t respond to TMPRSS2 activation, these mice were protected from becoming obese even when eating high-fat diets. Their blood sugar control remained normal because the appetite-control hormones could still function properly. This shows that TMPRSS2 is a direct cause of the hormone problems seen in obesity, not just a side effect.
When researchers either removed the TMPRSS2 gene entirely or used drugs to block it in obese mice, the beneficial hormones started working again. Blood sugar control improved significantly, and the mice showed better metabolic health. This demonstrates that blocking TMPRSS2 could potentially reverse some of the metabolic damage caused by obesity.
The study revealed that TMPRSS2 works through a specific molecular pathway involving a protein called PAR2. This pathway controls how much GIP (another appetite-regulating hormone) is released after eating. The research also showed that TMPRSS2 specifically affects the ghrelin pathway, which is important for signaling hunger and triggering GLP-1 release. Other similar proteins in the gut didn’t have the same blocking effect, showing that TMPRSS2 is uniquely important for this problem.
Current obesity treatments like semaglutide (Ozempic) and tirzepatide (Zepbound) work by mimicking GLP-1 and GIP hormones that the body isn’t making enough of in obesity. This research explains why the body stops making these hormones properly—TMPRSS2 actively blocks them. Previous research knew these hormones were reduced in obesity but didn’t understand the mechanism. This study identifies TMPRSS2 as a key reason why, suggesting a different approach: fixing the underlying problem rather than just replacing the missing hormones.
This research was conducted entirely in mice, so the findings may not directly translate to humans. The study didn’t test whether blocking TMPRSS2 would work as a treatment in living, freely-behaving mice over long periods. The abstract doesn’t provide detailed sample sizes for each experiment, making it difficult to assess statistical confidence. Additionally, the research doesn’t address whether TMPRSS2 blocking would be safe long-term in humans, since this protein also plays roles in other body systems. Finally, the study doesn’t compare TMPRSS2 blocking to existing obesity medications to see which approach might be more effective.
The Bottom Line
Based on this research, blocking TMPRSS2 appears promising as a potential new obesity treatment approach (moderate confidence level, as this is early-stage research). However, this is not yet ready for human use—much more research is needed. Current evidence-based recommendations remain: maintaining a healthy diet, regular physical activity, and consulting healthcare providers about existing medications like GLP-1 agonists if appropriate. This research suggests future treatment options may become available, but shouldn’t change current medical practice.
This research is most relevant to people with obesity or type 2 diabetes, as well as researchers developing new obesity treatments. It’s also interesting for people who don’t respond well to current GLP-1 medications, as blocking TMPRSS2 might work through a different mechanism. People without obesity or metabolic disease don’t need to change anything based on this research. Healthcare providers treating obesity should be aware of this emerging research direction.
This is very early-stage research. Even if TMPRSS2 blocking proves effective in humans, it typically takes 5-10 years to develop a new medication and get it approved. Don’t expect treatments based on this research to be available soon. Current obesity treatments remain the best option for people who need help now.
Want to Apply This Research?
- Track fasting blood glucose levels weekly and appetite/hunger levels daily on a 1-10 scale. This creates a baseline for comparing future treatments and helps identify patterns in how diet affects blood sugar control.
- Users could log meals and rate their hunger before and after eating to understand their personal appetite patterns. This data becomes valuable if TMPRSS2-blocking treatments become available, as it provides a baseline for measuring improvement.
- Establish a 12-week tracking period measuring: fasting glucose (if user has access to testing), daily hunger ratings, weight, and energy levels. This creates a personal health baseline that can be compared if new treatments become available, and helps users understand their individual metabolic patterns.
This research describes early-stage laboratory studies in mice and has not been tested in humans. These findings should not be used to make changes to current medical treatment or medications. If you have obesity, diabetes, or metabolic concerns, consult your healthcare provider about evidence-based treatments currently available. This research is informational only and represents potential future directions in obesity treatment, not current medical recommendations. Do not stop or change any medications based on this information.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.